Develops cancer therapies targeting genetic vulnerabilities discovered through large-scale CRISPR tumor screens.
Develops cancer therapies targeting genetic vulnerabilities discovered through large-scale CRISPR tumor screens.
Has no approved product and so no sales; spending is funded by money raised from investors and by payments under partnerships with larger drug makers. Each clinical readout on its lead programs shapes both the funding it can raise and the value of any partnership.
Moat: none (IP / patents, data). Proprietary CRISPR-based target discovery platform but still clinical-stage with no approved drugs.
Headquarters: Boston, Massachusetts, US · Founded: 2017 · Employees: 137
Size Tango Therapeutics (TNGX) is a United States Health Care company (Biotechnology) with a market value of $3.71B, the 1388th largest of 3,085 United States companies the cockpit tracks. Shares closed at $21.89 on 18 Nov 2026.
Performance Over six months the shares gained 3.8%, against +2.1% for the median peer and -2.2% for the United States market (cap-weighted) — 11th highest of 21 in its peer set.
Growth Revenue fell 100.0% over the last twelve months (peer median +7.3%).
Short interest Short interest is 28.6% of the free float (30 Oct 2026).
Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $62.4M | $42.1M | $36.5M | $24.9M |
| Revenue growth | — | +48% | +15% | +47% | — |
| Gross profit | -$1.79M | $60.1M | $39.6M | $34.1M | $20.8M |
| EBITDA | -$227M | -$109M | -$143M | -$112M | -$107M |
| Net income | -$208M | -$102M | -$130M | -$102M | -$108M |
| Free cash flow | -$150M | -$140M | -$132M | -$120M | -$117M |
| Capital expenditure | $277,000 | $1.05M | $754,000 | $1.53M | $7.69M |
| Total debt | $31.2M | $33.6M | $36.5M | $38.9M | $41.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Tango Therapeutics TNGX | $3.71B | +4% | -100% | n/a | n/a | n/a |
| IDEAYA Biosciences IDYA | $2.56B | -11% | -83% | -1,267% | 48.0× | n/a |
| Revolution Medicines RVMD | $34.6B | +6% | n/a | -853% | 162.6× | n/a |
| Amgen AMGN | $240B | +34% | +9% | 36% | 7.2× | 1.6% |
| Bristol Myers Squibb BMY | $122B | +3% | +4% | 33% | 3.1× | -13.1% |
| AstraZeneca AZN.L | $278B | -2% | +5% | 23% | 5.0× | 14.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | TNGX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -13.3% | -5.3% | 5th lowest of 21 |
| 6-month return | +3.8% | +2.1% | 11th highest of 21 |
| Distance from 52-week high | -36.4% | -31.1% | 7th lowest of 21 |
| Revenue growth (TTM) | -100.0% | +7.3% | lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Tango Therapeutics TNGX | United States | $3.71B | +4% | -100% | n/a | n/a | n/a | n/a |
| JOINN Laboratories (China) 6127.HK | Hong Kong | $3.70B | +6% | +17% | -4% | 12.4× | n/a | n/a |
| Relay Therapeutics RLAY | United States | $3.65B | +27% | +24% | -3,095% | 273.1× | n/a | n/a |
| AbCellera Biologics ABCL | United States | $3.60B | +141% | +92% | -298% | 43.4× | n/a | n/a |
| Disc Medicine IRON | United States | $3.55B | +16% | n/a | n/a | n/a | n/a | n/a |
| CRISPR Therapeutics CRSP | United States | $3.90B | -17% | -34% | -2,059% | 95.6× | n/a | n/a |
| Beijing Tiantan Biological Products 600161.SS | China | $3.47B | -13% | -13% | 21% | 4.5× | 2.2% | +12.5% |
| Iovance Biotherapeutics IOVA | United States | $3.46B | +111% | +51% | -61% | 8.3× | n/a | n/a |
| Lin BioScience 6696.TWO | Taiwan | $3.98B | +305% | n/a | n/a | n/a | n/a | n/a |
| Caliway Biopharmaceuticals 6919.TW | Taiwan | $3.32B | -25% | -54% | -6,983% | 6,626.2× | n/a | n/a |
| Enliven Therapeutics ELVN | United States | $3.30B | +7% | n/a | n/a | n/a | n/a | n/a |
| Beijing Wantai Biological Pharmacy Enterprise 603392.SS | China | $4.20B | -43% | +8% | -35% | 12.7× | n/a | n/a |
| 3SBio 1530.HK | Hong Kong | $4.28B | -31% | +102% | 61% | 0.9× | n/a | n/a |
| Hualan Biological Engineering 002007.SZ | China | $3.20B | -17% | -11% | 17% | 5.3× | 15.8% | -1.8% |
| Virbac VIRP.PA | France | $3.20B | -4% | +4% | 15% | 2.1× | 5.8% | +9.4% |
| Xeris Biopharma XERS | United States | $3.10B | +173% | +38% | 13% | 8.7× | 29.5% | +70.2% |
| Changchun High-Tech Industry (Group) 000661.SZ | China | $4.52B | -13% | -18% | -1% | 2.8× | 32.4% | +7.1% |
| Edgewise Therapeutics EWTX | United States | $4.53B | +26% | n/a | n/a | n/a | n/a | n/a |
| Shanghai RAAS Blood Products 002252.SZ | China | $4.57B | -15% | -22% | 17% | 5.4× | n/a | n/a |
| ADMA Biologics ADMA | United States | $3.01B | +58% | +6% | 45% | 6.0× | -0.8% | +64.6% |
| Telix Pharmaceuticals TLX.AX | Australia | $2.99B | -2% | +27% | -1% | 3.8× | n/a | n/a |